Abstract
Summary and Conclusions
The blood hydrolysate Sanguinin was tested in vivo in 268 albino mice accompanied by 221 untreated controls for its effectiveness against the beta-hemolytic Streptococcus zooepidemicus. Sanguinin solution (20 mg/ml) was inoculated subcutaneously (0.25 to 1.0 mg/mouse daily, usually for 4-6 days) either prior or after infection. Suppressive effect on the course of the infection was noted in all series of treated mice. A significant increase in survival time was noted in the pretreated series with an average survival percentage of 38.9 compared with 6.0 of the total of untreated controls. It does not appear that a direct correlation can be established between the survival rates and the intake of Sanguinin or the length of its administration, however, pretreatment seems to be of decisive value.
Get full access to this article
View all access options for this article.